As the global healthcare landscape matures in 2026, the Plague Market analysis reveals a sector defined by dual priorities: rapid clinical intervention and long-term biodefense readiness. While Yersinia pestis infections remain sporadic, the market has seen a significant valuation surge, reaching approximately $15.1 billion across major global markets. This growth is largely driven by a renewed...
Tiếng Việt 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)